Novartis AG

Core Business

Novartis AG is a global pharmaceutical leader with significant CGT operations spanning CAR-T cell therapy, AAV gene therapy, and radioligand therapies. Its flagship CGT products include Kymriah — the world's first approved CAR-T therapy — and Zolgensma, a blockbuster AAV gene therapy for spinal muscular atrophy generating $1.23 billion in 2025 revenue. Novartis generated $54.53 billion in total 2025 revenue.

Global Presence

Headquartered in Basel, Switzerland, Novartis operates across 140+ countries with 78,000 employees. Its dedicated CGT manufacturing network spans seven facilities across the US, Switzerland, France, Japan, and Australia, representing one of the industry's most geographically diverse production footprints.

Key Strengths

Novartis combines deep CGT expertise — as the pioneer of both the first approved CAR-T therapy (Kymriah, 2017) and the first systemic AAV gene therapy (Zolgensma, 2019) — with unparalleled global commercial infrastructure. The company's $54.53 billion revenue base funds extensive R&D and manufacturing investment, while Zolgensma's commercial success demonstrates the long-term viability of one-time curative gene therapies.

VerityRank Score

Novartis AG achieves a VerityRank Score of 96/100, reflecting its pioneering role in CGT commercialization, extensive global manufacturing network, and robust financial foundation for continued leadership.